Literature DB >> 10382738

IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: a mechanism for its antitumor activity?

F Y Yue1, R Geertsen, S Hemmi, G Burg, J Pavlovic, E Laine, R Dummer.   

Abstract

IL-12 enhances cytolytic activity and proliferation of NK and T cells, and induces cytokines such as IFN-gamma. No direct effects on non-hematopoietic cells have been shown. This study investigates the effects of IL-12 on melanoma cells in vitro. We analyzed 15 melanoma cell cultures and 1 melanoma cell line. Out of 16 samples 13 expressed the beta chain of the IL-12 receptor (IL-12Rbeta). Preincubation with IL-12 increased the surface levels of human leukocyte antigen (HLA) class I, HLA class II and intercellular adhesion molecule (ICAM)-1 of those cultures with IL-12Rbeta expression. The effects of IL-12 on HLA class I could be blocked by an IL-12-neutralizing monoclonal antibody (mAb), but not by an mAb against IFN-gamma. Melanoma cells transduced with IL-12 expressed enhanced levels of HLA class I, HLA class II and ICAM-1 compared to controls. Co-incubation of the melanoma cells with allogeneic peripheral blood mononuclear cells (PBMC) resulted in enhanced proliferation and increased production of IL-2 and IFN-gamma after pretreatment with IL-12. IL-12 pretreatment increased the susceptibility of melanoma cells to lysis by prestimulated autologous PBMC. Since IL-12 induced immunocritical surface molecules on melanoma cells, it might be beneficial during immune interventions in melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10382738     DOI: 10.1002/(SICI)1521-4141(199906)29:06<1762::AID-IMMU1762>3.0.CO;2-F

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

Review 1.  Advances in the development of intralesional therapies for melanoma.

Authors:  Daniel Y Wang; Douglas B Johnson
Journal:  Melanoma Manag       Date:  2016-11-29

Review 2.  HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.

Authors:  Luke Maggs; Ananthan Sadagopan; Ali Sanjari Moghaddam; Soldano Ferrone
Journal:  Trends Cancer       Date:  2021-09-03

Review 3.  Plasmid IL-12 electroporation in melanoma.

Authors:  Edward Cha; Adil Daud
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

Review 4.  Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Immunotherapy       Date:  2016-07       Impact factor: 4.196

5.  In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma.

Authors:  A Kikuchi; M Nieda; C Schmidt; Y Koezuka; S Ishihara; Y Ishikawa; K Tadokoro; S Durrant; A Boyd; T Juji; A Nicol
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.